Mutation of Fnip1 is Associated with B-cell Deficiency, Cardiomyopathy, and Elevated AMPK Activity

Owen M. Siggs,Alexander Stockenhuber,Mukta Deobagkar-Lele,Katherine R. Bull,Tanya L. Crockford,Bethany L. Kingston,Greg Crawford,Consuelo Anzilotti,Violetta Steeples,Sahar Ghaffari,Gabor Czibik,Mohamed Bellahcene,Hugh Watkins,Houman Ashrafian,Benjamin Davies,Angela Woods,David Carling,Arash Yavari,Bruce Beutler,Richard J. Cornall

DOI: https://doi.org/10.1073/pnas.1607592113

2016-01-01

Abstract:Significance Cellular metabolism is tightly regulated by AMP-activated protein kinase (AMPK): the function of which is influenced by folliculin (FLCN), folliculin-interacting protein (FNIP)1, and FNIP2. FLCN is a known tumor-suppressor protein that is mutated in Birt–Hogg–Dubé syndrome, whereas FNIP1 and FNIP2 are binding partners of FLCN. Previous reports have suggested that the FLCN/FNIP1/FNIP2 complex acts a positive regulator of AMPK, whereas other reports suggest the opposite. Using a new mouse model of FNIP1 deficiency, our findings support the latter: we found that mutation of Fnip1 leads to B-cell deficiency and the development of a cardiomyopathy similar to mice and humans with gain-of-function mutations in AMPK.